$WORX

SCWorx Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Middleton, MA, Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- SCWorx Corp ( Nasdaq: WORX ) ( "SCWorx" or the "Company" ) , a software-as-a-service company focused on data management for healthcare providers received written notification from the Listing Qualification Department of The Nasdaq Stock Market ...

Original reporting
GlobeNewswire · SCWorx Corp.
Published Oct 14, 2025, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2025, 3:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SCWorx Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement — source image
Decision brief

The 30-second read

$WORXNeutralLow
01

Why it matters

The extension provides temporary relief, possibly stabilizing the stock price in the short term but does not address underlying issues.

02

Market read

The news is relevant primarily to existing shareholders and short-term traders focusing on Nasdaq-listed healthcare stocks.

03

What to watch

Potential underlying company performance issues or market conditions affecting Nasdaq compliance.

Timing: short-term (next 1-2 weeks)

Background

SCWorx is a healthcare data management company listed on Nasdaq, which has faced compliance and regulatory challenges.

Company-level read

Ticker impact

$WORXNeutralMedium confidence
Context

The news pertains directly to SCWorx (WORX), a Nasdaq-listed healthcare data management company, which is relevant for traders interested in healthcare and biotech sectors.

Expected impact

Limited immediate price movement expected; potential for slight positive bias if the extension alleviates concerns.

Evidence & confidence

The news confirms a temporary compliance extension, which may reduce immediate negative sentiment but does not guarantee a positive trend. Market reaction will depend on subsequent compliance and company performance.

Market effects

Healthcare data management sector may experience minimal impact; broader biotech and healthcare sectors are unaffected.

Limited regional impact, primarily affecting Nasdaq-listed healthcare companies.

Negligible; the news is specific to a single company and exchange.

Counterpoint

The extension may be viewed skeptically, indicating ongoing compliance issues that could lead to future delisting if not resolved.

Key entities

  • SCWorx Corp.

    Healthcare data management firm listed on Nasdaq.

Related articles

Med

SCWorx Corp.: SCWorx Receives Nasdaq Hearings Panel Partial Compliance Letter for the Company's Continued Listing on the Nasdaq Capital Market

SCWorx Corp. said Nasdaq’s Hearings Panel issued a partial compliance letter confirming completion of the first benchmark in its approved plan to regain compliance for continued listing. The remaining requirement is to meet the Nasdaq minimum bid price of at least $1.00 for 20 consecutive trading days, under Listing Rule 5815(c)(4).

$CWMed

Curtiss-Wright Slides As Investors Question CEO Handoff

Curtiss-Wright (CW) shares fell as investors reacted to a planned leadership transition, with the current COO set to become CEO in 2027. Concerns about strategic continuity and execution risk were raised, despite the company's strong financial position and growth prospects. Quarterly results may be volatile due to cash conversion and supply chain pressures.

$HCAMed

BMO starts HCA Healthcare stock at Outperform on growth outlook

BMO Capital initiated coverage on HCA Healthcare (NYSE:HCA) with an Outperform rating and $495 price target, citing growth drivers like demographic trends and digital transformation. HCA trades at $438.16 with $95.43B market cap, and reported Q2 2026 earnings beating estimates but lowered full-year guidance. Analysts have mixed reactions with varied price targets and ratings.

$BAMed

Boeing wins $33.4 million Air Force avionics contract

Boeing (BA) secured a $33.4M contract from the U.S. Department of War for C-17 Avionics Integration work, with completion expected by April 2032. The contract, awarded via a sole-source process, addresses obsolescence and maintains lab functionality. Funds were allocated from fiscal 2026 operations and maintenance budgets.